Table 1.
The effects of brain natriuretic peptide (BNP) infusion on renal function, the renin angiotensin II aldosterone system and hemodynamics in normal subjects and patients with heart failure and hypertension.
Study/Reference | Dosage of BNP pmol/kg/min | GFR | RPF | Urine Volume | Urine Na | Urine cGMP | Urine Aldo | Plasma cGMP | PRA | AngII | Plasma Aldo | MAP | HR | CO | SVR | PCWP |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Normal Subjects | ||||||||||||||||
McGregor. J. Clin. Endocrinol. Metab. 1990 [36] | 2 | ↑↔ * | ↑ | ↓ | ↓ | ↔ | ↔ | |||||||||
Yoshimura. Circulation. 1991 [37] | 30 | ↑ | ↑ | ↑ | ↔ | ↓ | ↓ | ↑ | ↑ | ↓ | ↓ | |||||
Holmes. J. Clin. Endocrinol. Metab. 1993 [9] | 2 | ↔ | ↑ | ↑ | ↑ | ↓↔ * | ↓ | ↔ | ↑ | |||||||
Cheung. Clin. Sci. 1994 [38] | 0.4 | ↔ | ↔ | ↑ | ↔ | ↔ | ||||||||||
Florkowski. Am. J. Physiol. 1994 [39] | 2(+ANP(2)) ** | ↔ | ↑ | ↑ | ↑ | ↔ | ↔ | ↔ | ↓ | ↔ | ||||||
La Villa. J. Clin. Endocrinol. Metab. 1994 [40] | 4 | ↑ | ↑ | ↑ | ↑ | ↑ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ||||
La Villa. Hypertension. 1995 [41] | 0.25 and 0.5 | ↔ | ↔ | ↔ | ↑ | ↑ | ↓ | ↓ | ↔ | ↔ | ||||||
Lazzeri. Cardiology. 1995 [42] | 4, 8, 10, 12 | ↑ | ↔ | ↔ | ↑ | ↔ | ↔ | |||||||||
Hunt. J Clin. Endocrinol. Metab. 1996 [43] | 2 | ↔ | ↑ | ↑ | ↑ | ↓↔ * | ↓ | ↓ | ↔ | ↑ | ||||||
Yasue. J Card. Fail. 1996 [44] | 30 | ↑ | ↑ | ↑ | ↑ | ↓ | ↑ | ↓ | ↓ | |||||||
Jensen. Am. J. Phy.1998 [35] | 1, 2 and 4 | ↑ | ↓ | ↑ | ↑ | ↑ | ↑ | ↓ | ↔ | ↔ | ↔ | ↔ | ||||
Jensen. Clin. Sci. 1999 [5] | 2 | ↑ | ↓ *** | ↔ | ↑ | ↑ | ↑ | ↓ | ↔ | ↔ | ↑ | ↔ | ||||
van der Zander. Am. J. Physiol. 2003 [45] | 4 | ↑ | ↔ | ↑ | ↑ | ↑ | ↔ | ↔ | ↓↔ * | ↔ | ||||||
Summarized | ↑ | ↔ | ↑ | ↑ | ↑ | ↑ | ↓↔ | ↔ | ↓ | ↔ | ↔ | ↔ | ↔ | ↓ | ||
Patients with Heart Failure | ||||||||||||||||
Yoshimura. Circulation. 1991 [37] | 30 | ↑ | ↑ | ↑ | ↔ | ↓ | ↓ | ↑ | ↑ | ↓ | ↓ | |||||
Marcus. Circulation. 1996 [46] | 1 to 30 | ↔ | ↑ | ↑ | ↑ | ↓ | ↓ | ↑ | ↓ | ↓ | ||||||
Yasue. J. Card. Fail. 1996 [44] | 30 | ↔ | ↑ | ↑ | ↑ | ↔ | ↔ | ↓ | ↓ | |||||||
Lainchbury. HTN 1997 [47] | 3.3 | ↔ | ↔ | ↑ | ↔ | ↔ | ↓ | ↔ | ↔ | ↓ | ↓ | |||||
Abraham. J. Cardiac. fail. 1998 [48] | 7.5, 15 | ↔ | ↔ | ↔ | ↔ | ↑ | ↔ | ↓ | ↓ | ↔ | ↑ | ↓ | ↓ | |||
Jensen. Clin. Sci. 1999 [5] | 2 | ↔ | ↔ | ↔ | ↑ | ↑ | ↑ | ↓ | ↔ | ↔ | ↑ | ↔ | ||||
Wang. Am. J. Trans. Res. 2016 [49] | A bolus followed by 2 to 6 for 72 h | ↓ | ↓ | |||||||||||||
Summarized | ↔ | ↔ | ↑ | ↑ | ↑ | ↑ | ↔ | ↔ | ↓ | ↓ | ↔ | ↑ | ↓ | ↓ | ||
Patients with Hypertension | ||||||||||||||||
Richards. J. Hypertension. 1993 [50] | 2 | ↔ | ↑ | ↑ | ↔ | ↑ | ↔ # | ↓ | ↔ | ↔ | ||||||
Lazzeri. Am. J. Hypertension. 1995 [51] | 4 | ↑ | ↑ | ↑ | ↑ | ↔ | ↔ | ↔ | ↔ | ↔ | ||||||
Pidgeon. Hypertension. 1996 [52] | 2 | ↑ | ↑ | ↔ | ↑ | ↓ | ↓ | ↓ | ↑ | |||||||
Summarized | ↑ | ↑ | ↑ | ↑ | ↔ | ↓ | ↔ | ↔ |
ANP, atrial natriuretic peptide; cGMP, cyclic guanosine monophosphate; CO, cardiac output; GFR, glomerular filtration rate; HR, heart rate; MAP, mean arterial pressure; PCWP, pulmonary capillary wedge pressure; PRA, plasma renin activity; RPF, renal plasma flow; SVR, systemic vascular resistance. * marginal significance. ** BNP(2)+ANP(2) vs ANP(2) alone. *** after the infusion. # Plasma renin concentration.